PharmaEngine announced Wednesday the execution of a
Collaboration and Research Agreement with Guangzhou BeBetter Medicine
Technology Co., Ltd. (BeBetter). The two companies will collaborate to
design, synthesize and develop new chemical entities (“drug candidates”)
against predefined targets in oncology. This collaboration opens a new
chapter for partnership between Taiwan and China in searching for novel
anti-cancer drugs.
Under the terms of the agreement, PharmaEngine will hold the exclusive
worldwide rights of manufacturing, development and commercialization of
new drug candidates with the exception of China, while BeBetter will
keep the respective rights in China (including Hong Kong and Macau).
BeBetter is responsible for discovering optimized compounds for
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in